Background: Current efforts to develop stem cell therapy as a novel treatment for
| INTRODUCTION
Much of our understanding of developmental and pathophysiological processes in the human gut has been based on results of studies of experimental animal models. However, translational research requires models that use human intestine. Most studies of the human gastrointestinal system at the cellular and molecular level have relied either on biopsy material, organ cultures, or human cell lines. However, the ability to study development, physiology, and pathophysiology of the human enteric nervous system (ENS) using these models is limited.
In particular, the potential development of enteric neuronal stem cell (ENSC) therapy as a promising approach to replace missing or abnormal neurons in patients with enteric neuropathies would be facilitated by an experimental platform in which (i) the tissue is of human origin and (ii) the disease can be induced and therapy implemented and evaluated over time.
One approach to the study of the human gut has been to transplant human fetal gut subcutaneously in immunosuppressed mice. 1, 2 This model has been described in detail, and has primarily been used for study of enteropathogen-host interactions. [3] [4] [5] [6] [7] [8] [9] [10] However, with the exception of one acknowledgment that the myenteric plexus exists in these human xenografts, 1 there has been no mention of the ENS in any studies of this model. Here, we describe the characteristics of the ENS in human fetal gut transplanted and maintained in SCID mice over the course of several months. We show that the fundamental neuronal and glial cell types and neuronal organization in the xenografts are as expected from samples of normal human tissue. We also describe a novel experimental model which entails transplanting human fetal gut onto the mesentery in the mouse abdominal cavity, adjacent to the host gut. Here too, the donor gut demonstrates normal cytoarchitecture and cellular differentiation, including formation of a normal enteric nervous system. These novel experimental platforms provide a robust system for long-term studies of human intestine and for furthering the development of cell-based therapies for neurointestinal diseases. Women undergoing legal termination of pregnancy gave written, informed consent for use of fetal tissue in this study. Human fetal small bowel 12-18 weeks gestational age was implanted subcutaneously on the dorsum of the mouse as described previously [3] [4] [5] or intra-abdominally as described below. All surgical procedures were performed in an aseptic environment in a laminar flow HEPA- and to fix it to the jejunum. Care was taken to avoid injuring the mouse mesenteric vessels. The abdomen was closed using standard surgical techniques. After surgery, the mice were provided with enrofloxacin-medicated water (Bayer Animal HealthCare AG) for 7 days and closely monitored daily for behavior, reactivity, appearance, and defecation. Grafts developed in situ for 12-16 weeks prior to manipulation.
| MATERIALS AND METHODS

| SCID mouse human intestinal xenotransplant models
| Tissue processing
Mice were sacrificed and xenograft tissues trisected for histology, fluorescence staining, and electron microscopy. Samples for histological analysis were fixed in neutral buffered 4% paraformaldehyde (PFA) and paraffin embedded. Alkaline phosphatase staining using embedding medium. For electron microscopy, samples were fixed in 4% buffered glutaraldehyde followed by dehydration in graded ethanol, and the samples were embedded in a Polybed/Araldite 6500 mixture (Polysciences, Warrington, Pennsylvania, USA). The ultrathin
Key Points
• Reliable and experimentally tractable models are needed to study the pathophysiology of enteric neuropathies and to develop novel cell-based treatments for these diseases.
• The enteric nervous system of fetal human intestine develops normally in murine subcutaneous and abdominal xenografts.
• Abdominal xenografts represent a novel and useful method for studying the enteric nervous system, neurointestinal diseases, and enteric neuronal stem cell transplantation.
sections were contrasted with uranyl acetate and lead citrate and studied with a Tecnai 12 (Phillips, Eindhoven, The Netherlands) TEM equipped with MegaView II CCD camera and AnalySIS version 3.0 software.
| Immunohistochemistry
Paraffin embedded tissues were sectioned at a thickness of 5 μm, CA, USA) and the avidin-biotinylated horseradish peroxidase complex.
Staining was developed using 3,3′-diaminobenzidine (Vector). 
| RESULTS
| Abdominal xenografts
Intestinal tissue, including either small or large intestine, was harvested from human fetuses at 12-18 weeks gestation and transplanted into immunocompromised SCID mice. Recipient mice were 6-8 weeks of age. The graft was positioned along the mesenteric side of the jejunum of recipient mice ( Figure 1A ). Prior to transplantation, the intestine was confirmed to have normal cytoarchitecture, including a normal-appearing ENS ( Figure 1B) . A total of 18 mice were transplanted with fetal gut segments from nine different donors. Recipients were maintained for 6-8 weeks and graft survival was 100%. At the time of harvest, the graft shows obvious growth ( Figure 1C ) and preserved histology, as shown in Figure 1D , which demonstrates the grafted human intestine adjacent to the host mouse intestine. Despite the large size of the transplanted graft relative to the host intestine, no evidence of obstruction of the mouse intestine was observed.
The ENS of the xenograft contains normal-appearing enteric ganglia ( Figure 1E ), shown by immunofluorescent labeling of both submucosal and myenteric plexuses with the enteric neuronal antibody, Tuj1
( Figure 1F ). S100 + glial cells are demonstrated both in the ganglia ( Figure 1G ) and in the lamina propria ( Figure 1H ). The ganglia also contain Hu+ neurons ( Figure 1G ), as well as enteric neurons immunoreactive to PGP9.5 ( Figure 1I ), calretinin ( Figure 1J ), and nNOS ( Figure 1K ). c-Kit-expressing interstitial cells of Cajal (ICC) are also present ( Figure 1L ).
| Subcutaneous xenografts
Human fetal intestine was transplanted subcutaneously into SCID mice (Figure 2A ), where they were maintained for 12-16 weeks.
Following harvesting of the xenograft, the intestine appeared viable and grossly normal. Epithelial cell proliferation within the crypts was confirmed by PCNA staining ( Figure 2B ). Normal development of the smooth muscle layers ( Figure 2C ) and ENS ( Figure 2D ) were also confirmed by immunostaining. As shown in Figure 2D , enteric ganglia 
| DISCUSSION
Subcutaneous transplantation of fetal rodent intestine into rodent hosts was described over 45 years ago 11 and has been extensively studied since then with respect to its anatomical and functional development. 12 Transplantation of fetal human intestine into a nude mouse was first described in 1991. 2 Human fetal small and large intestine was able to be maintained for up to 6 months in 62% of the transplants and demonstrated neovascularization with age-appropriate maturation and normal gross histology of all intestinal elements. Studies using this platform have focused on investigation of human-specific enteropathogens and the inflammatory and immunological responses they evoke. [3] [4] [5] [6] [7] [8] [9] [10] 13 There has been no study of the human ENS in this model. However, Tanaka et al. 14 performed a careful characterization of the ENS in fetal rat gut transplanted into rats. These workers reported hyperganglionosis and hyperinnervation in the transplanted rat intestine.
In the present study of human grafts, we observed normal development and differentiation of enteric neurons and glial cells.
Further analyses are needed to more precisely determine whether neuronal and glial cell numbers, morphology, or subtypes differ from normal human intestine. Moreover, we observed spontaneous peristaltic activity when the grafts were harvested, suggesting that the gut remains functionally active throughout the transplantation period, although quantitative analyses of motility are needed.
One goal of this study was to develop a novel platform that would allow long-term survival, growth, and maturation of fetal human intestine in a vascularized environment and thereby provide a new way to study human fetal ENS maturation and the development of regenerative stem cell-based therapies for neurointestinal diseases. In comparing the merits of intra-abdominal and subcutaneous grafts, we did not detect any histologic differences in their phenotypes. While technically more difficult to perform due to the need for laparotomy, intra-abdominal grafts may have several advantages over subcutaneous grafts. First, they are readily vascularized by the intestinal mesentery on which they develop. Second, their growth may be less constrained than in the subcutaneous space. Third, there may be advantages to being in the microenvironment of the host intestine rather than in a location where the gut does not normally reside.
Neurointestinal diseases, including esophageal achalasia, gastroparesis, chronic intestinal pseudo-obstruction, and Hirschsprung disease, represent major causes of morbidity. 15 Despite this, current 
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